Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oramed Pharma (ORMP)

Oramed Pharma (ORMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,330
  • Shares Outstanding, K 40,312
  • Annual Sales, $ 1,340 K
  • Annual Income, $ 5,530 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 1.77
  • Price/Sales 69.49
  • Price/Cash Flow N/A
  • Price/Book 0.61

Options Overview Details

View History
  • Implied Volatility 327.58% ( -168.17%)
  • Historical Volatility 37.59%
  • IV Percentile 93%
  • IV Rank 35.59%
  • IV High 883.92% on 01/22/24
  • IV Low 20.14% on 03/15/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 285
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 1,297
  • Open Int (30-Day) 1,437

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.03
  • Low Estimate -0.02
  • Prior Year -0.08
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.13 +9.86%
on 11/18/24
2.43 -3.70%
on 11/06/24
-0.03 (-1.27%)
since 10/22/24
3-Month
2.13 +9.86%
on 11/18/24
2.75 -14.91%
on 09/13/24
-0.13 (-5.26%)
since 08/22/24
52-Week
2.00 +17.00%
on 06/10/24
3.67 -36.24%
on 02/27/24
+0.21 (+9.86%)
since 11/22/23

Most Recent Stories

More News
Oramed: Q2 Earnings Snapshot

Oramed: Q2 Earnings Snapshot

ORMP : 2.34 (+1.30%)
Oramed: Q1 Earnings Snapshot

Oramed: Q1 Earnings Snapshot

ORMP : 2.34 (+1.30%)
Oramed: Q3 Earnings Snapshot

Oramed: Q3 Earnings Snapshot

ORMP : 2.34 (+1.30%)
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

/PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving...

SCLX : 0.5208 (-5.57%)
ORMP : 2.34 (+1.30%)
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE:ORMP) today announced that on September 21, 2023, Oramed and Scilex Holding Company ("Scilex")...

ORMP : 2.34 (+1.30%)
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) announced today that it has signed a non-binding term sheet with Hefei...

ORMP : 2.34 (+1.30%)
Oramed to Present at the 83rd American Diabetes Association Conference

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract...

ORMP : 2.34 (+1.30%)
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will...

ORMP : 2.34 (+1.30%)
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) announced today that Hefei Tianhui Biotechnology Co. Ltd. (HTIT), a...

ORMP : 2.34 (+1.30%)
Oramed: Q1 Earnings Snapshot

Oramed: Q1 Earnings Snapshot

ORMP : 2.34 (+1.30%)

Business Summary

Oramed Pharmaceuticals, Inc. is a pharmaceutical company operating as a developer of oral drug delivery systems. The Company is developing orally ingestible insulin capsules for the treatment of diabetes as well as delivery solutions for other drugs and vaccines. Oramed Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 2.48
2nd Resistance Point 2.43
1st Resistance Point 2.39
Last Price 2.34
1st Support Level 2.30
2nd Support Level 2.25
3rd Support Level 2.21

See More

52-Week High 3.67
Fibonacci 61.8% 3.03
Fibonacci 50% 2.84
Fibonacci 38.2% 2.64
Last Price 2.34
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar